Menu
0
0

Your Cart is Empty

Tetracycline-Inducible Systems and Vectors

Cellecta offers a range of inducible lentiviral vectors that enable modulation of both short RNA sequences (e.g., shRNA and sgRNA), and standard mRNA transcripts.

  • Two tet-inducible systems for both cDNA and short RNA (e.g., sgRNA, shRNA) expression
  • Tightly regulated doxycycline-responsive promoters
  • All-in-one, single vector designs that include both the promoter and tet-responsive regulator

  • Cellecta provides inducible expression systems for both short RNA sequences, such as sgRNA and shRNA, using an expression cassette designed for RNA polymerase 3 with tet-responsive U6 or H1 promoters, as well as for inducible cDNA gene expression with the InDOXible tet-responsive RNA polymerase 2 promoter.

    Inducible sgRNA and shRNA: The inducible U6 (or H1) promoter driving sgRNA/shRNA expression in our constructs is driven by RNA polymerase 3, which transcribes short RNA expression, like rRNA and tRNA. We developed the tet-inducible U6 promoter in-house at Cellecta.

    Expression of cDNA: Most researchers are familiar with the tet-inducible expression system using a modified CMV promoter. Cellecta has developed an optimized Tet-Activated system regulated by the rtTA activator or tTA repressor.

    Cellecta offers all the tet-inducible vector options as part of its sgRNA, shRNA, and cDNA custom lentiviral vector construction services.

    short-RNA_sequences

  • (A) Inducible sgRNA and shRNA: Expression of sgRNA and shRNA is driven by the human U6 promoter. Cellecta has developed an inducible version of the U6 promoter using tet-operator control elements.

    (B) Inducible cDNA Expression: Cellecta’s Tet-Responsive InDOXible™ System regulates expression of cDNA using hybrid activator/repressor proteins and a modified CMV promoter.

    all-in-one-dox-on-vector

  • There are numerous applications where inducible gene expression can help advance research. Common applications include:

    • Inducible protein expression to evaluate gene function
    • Regulating gene activity to induce tumorigenesis, activate pathways, or stimulate phenotypes
    • Suppressing toxic gene expression until needed
    • Reversible activation or repression using CRISPRa, CRISPRi, or shRNA
    • Assessing gene function in response to drug treatments
    • Monitoring Cas9 induction using Cas9-BFP

Products